Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure
Open Access
- 26 April 2012
- journal article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 16 (5) , 1125-1133
- https://doi.org/10.1111/j.1582-4934.2011.01399.x
Abstract
Increased levels of intestinal VEGF are thought to worsen portal hypertension. The cause of the increase in the level of intestinal VEGF found during cirrhosis is not known. The aim of this study is to demonstrate a relationship between portal pressure (PP) and intestinal/ plasma VEGF levels in different stages of fibrosis/cirrhosis. In this experiment, rats were exposed to carbon tetrachloride (CCl4) for 6, 8 and 12 weeks. At the end of exposure, the three groups of rats exhibited three different stages of pathology: non-cirrhotic, early fibrotic and cirrhotic, respectively. For those rats and their age-matched controls, PP and intestinal/plasma VEGF levels were measured. Rats inhaling CCl4 for 12 weeks developed portal hypertension (18.02 ± 1.07 mmHg), while those exposed for 6 weeks (7.26 ± 0.58 mmHg) and for 8 weeks (8.55 ± 0.53 mmHg) did not. The rats exposed for 12 weeks also showed a 40% increase in the level of intestinal VEGF compared to the controls (P < 0.05), while those rats exposed to CCl4 inhalation for 6 and 8 weeks did not. There was a significant positive correlation between PP and intestinal VEGF levels (r2 = 0.4, P < 0.005). Plasma VEGF levels were significantly elevated in those rats exposed to 12 weeks of CCl4 inhalation (63.7 pg/ml, P < 0.01), compared to the controls (8.5 pg/ml). However, no correlation was observed between PP and plasma VEGF levels. It is concluded that portal pressure modulates intestinal VEGF levels during the development of cirrhosis.Keywords
This publication has 37 references indexed in Scilit:
- Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinomaDigestive and Liver Disease, 2009
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats #Hepatology, 2009
- Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic ratsGut, 2008
- Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat liversJournal of Hepatology, 2006
- Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive ratsJournal of Hepatology, 2005
- Implication of inflammation‐related cytokines in the natural history of liver cirrhosisLiver International, 2004
- Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APCMin/+ mouse modelCarcinogenesis: Integrative Cancer Research, 2003
- Circulating vascular endothelial growth factor levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damageClinical Science, 2000
- Expression of Vascular Endothelial Growth Factor by Cultured Endothelial Cells from Brain MicrovesselsBiochemical and Biophysical Research Communications, 1993